Opening: Doctor's Decision-Making Logic
In reproductive medicine clinics, every day patients come with reports asking the same question: "Doctor, do I need PGT-A?" This question seems simple, but answering it requires a comprehensive assessment of multiple dimensions including age, ovarian reserve, number of embryos, previous pregnancy history, and economic cost. PGT-A is not a universal technology; its value varies greatly among different populations. This article, from the perspective of a reproductive doctor, systematically deconstructs the true face of PGT-A technology in China.
What is PGT-A and what is its core function?
PGT-A (Preimplantation Genetic Testing for Aneuploidy) refers to preimplantation genetic screening for aneuploidy. In simple terms, before the embryo is transferred back into the uterus, 3-5 cells are taken from the trophectoderm cells of the blastocyst (the part that will later develop into the placenta) to test whether the chromosome number in these cells is normal. Embryos with a normal number of chromosomes are called euploid embryos, while those with too many or too few are called aneuploid embryos.
The core function of PGT-A is to reduce the miscarriage rate and increase the live birth rate per single transfer. It cannot increase the cumulative live birth rate, nor can it guarantee the absolute health of the child. For embryo arrest, biochemical pregnancy, and early miscarriage caused by abnormal chromosome numbers, PGT-A has a clear preventive value.
How doctors evaluate the clinical value of PGT-A
From a clinical decision-making perspective, the value of PGT-A depends on the patient's specific situation. For the following populations, the benefit of PGT-A is clear:
- Advanced maternal age (≥38 years): The error rate of oocyte meiosis increases with age, and the proportion of aneuploid embryos significantly increases. PGT-A can effectively reduce miscarriages caused by chromosomal abnormalities.
- Recurrent spontaneous miscarriage (≥2 times): After excluding uterine anatomical, endocrine, and immune factors, embryonic chromosomal abnormalities are one of the main causes of recurrent miscarriage.
- Repeated implantation failure (≥3 transfers of good quality embryos without pregnancy): Some cases of repeated failure are related to embryonic chromosomal abnormalities.
- Severe male factor infertility: An increased rate of sperm chromosomal aberrations can raise the risk of embryonic aneuploidy.
- History of pregnancy with chromosomal abnormalities: Previously having a fetus with aneuploidy (such as Down syndrome, Edwards syndrome, etc.).
However, for young patients with normal ovarian reserve and no adverse pregnancy history, the benefit of PGT-A is limited. If the number of embryos is not large (for example, only 1-2 blastocysts), the biopsy and testing process may cause embryo loss, thereby reducing the chance of transfer.
Aneuploidy rates and PGT-A benefits across different age groups
Age is the most important factor affecting the rate of embryonic chromosomal abnormalities. The following are common clinical data from reproductive centers in China for reference:
| Female Age | Blastocyst Aneuploidy Rate (approx.) | Clinical Benefit of PGT-A | Recommended Strategy |
|---|---|---|---|
| < 35 years | 20% - 30% | Limited benefit, not recommended for ≤2 blastocysts | Prioritize morphological grading transfer |
| 35 - 37 years | 30% - 40% | Some benefit, requires ≥3 blastocysts | Consider, decide based on embryo number |
| 38 - 40 years | 40% - 50% | Clear benefit, strongly recommended | Recommend PGT-A, need to accumulate blastocysts |
| 41 - 42 years | 50% - 65% | Significant benefit, but needs sufficient embryos | Recommend PGT-A, also assess oocyte yield expectation |
| > 42 years | > 65% | High benefit, but difficult to obtain embryos | Individualized assessment, consider egg donation option |
Note: The above data are based on clinical statistics from reproductive centers in China. Individual variation is significant, and this is for reference only.
Current status and policy differences of PGT-A technology in China
China has clear indication management for the clinical application of PGT-A. According to relevant regulations of the National Health Commission, the implementation of PGT (third-generation IVF) technology must meet medical indications and be carried out in approved medical institutions. Compared with countries like the United States and Thailand, China's indications for PGT-A are more strictly controlled and cannot be performed solely for "sex selection" or "pursuing better embryos."
At the technical level, mainstream reproductive centers in China generally use Next-Generation Sequencing (NGS) technology for PGT-A testing, with detection accuracy and coverage comparable to international advanced levels. Some centers also retain aCGH (array Comparative Genomic Hybridization) and FISH (Fluorescence In Situ Hybridization) technologies, but NGS has become the mainstream. PGT-A testing in China typically covers numerical abnormalities of all 23 pairs of chromosomes, and some platforms can also detect chromosomal deletions/duplications >5Mb.
Compared with foreign countries, the cost of PGT-A in China is relatively lower, with a single test costing approximately 20,000-50,000 RMB (including biopsy and testing), but this varies greatly between different regions and hospitals. In the United States, a single PGT-A test costs about 3,000-6,000 USD. In Thailand, it is about 2,000-4,000 USD.
Complete PGT-A process and timeline
From starting the cycle to transferring the embryo after PGT-A screening, the following steps are usually required:
- Ovarian stimulation (about 10-14 days)
- Egg retrieval surgery (30 minutes)
- In vitro fertilization and embryo culture (5-6 days)
- Blastocyst trophectoderm biopsy (1 day)
- Embryo freezing (immediately after biopsy)
- Genetic testing (7-14 days for report)
- Frozen embryo transfer (next menstrual cycle)
From egg retrieval to obtaining PGT-A test results, it takes approximately 14-21 days. Transfer is usually performed in the next menstrual cycle after obtaining the results, allowing sufficient time for endometrial preparation. The entire cycle from starting stimulation to completing the transfer typically takes 2-3 menstrual cycles.
Materials and conditions needed:
✔ Chromosome karyotype analysis report of both partners (to rule out structural abnormality carriers)
✔ Genetic counseling records (required by some centers)
✔ Informed consent form (fully understanding the limitations and risks of PGT-A)
✔ Sufficient number of blastocysts (generally recommended ≥3 to increase the probability of obtaining a euploid embryo)
Four technical details most easily overlooked
1. The dilemma of interpreting mosaic embryos
About 5%-10% of blastocysts exhibit mosaicism, meaning the embryo contains both chromosomally normal and abnormal cell lines. PGT-A only tests a few biopsied trophectoderm cells. If abnormal cells happen to be sampled, the entire embryo might be misjudged as abnormal; conversely, it could be missed. Whether mosaic embryos can be transferred is not yet fully standardized in domestic and international guidelines. The decision is generally made comprehensively based on the mosaic ratio, chromosome type, patient age, and number of embryos.
2. False negatives and false positives in PGT-A
Limited by the number of biopsied cells and the resolution of detection technology, the sensitivity of PGT-A is about 95%, and the specificity is about 99%. This means about 5% of aneuploid embryos may be misjudged as normal (false negative), and about 1% of normal embryos may be misjudged as abnormal (false positive). False positives can lead to the discarding of transferable embryos, which has a particularly significant impact on patients with few embryos.
3. Potential impact of biopsy on the embryo
The risk of damage to the embryo from trophectoderm biopsy is low, but not zero. Research data shows that the immediate survival rate of embryos after biopsy is about 97%-99%, but subsequent implantation ability may be slightly reduced (by about 2%-5%). For patients who already have a limited number of embryos, the loss caused by biopsy needs to be considered in the decision-making process.
4. PGT-A cannot increase the cumulative live birth rate
This is the most common cognitive blind spot. PGT-A increases the live birth rate per single transfer by screening for euploid embryos, but the total live birth opportunity (cumulative live birth rate) from one stimulation cycle does not increase because PGT-A was performed. In fact, because the biopsy and freezing process may cause embryo loss, the cumulative live birth rate for some young patients may even be slightly lower than that of a control group without biopsy.
Five cognitive pitfalls most easily fallen into
- Myth 1: PGT-A guarantees a healthy child. PGT-A only checks chromosome number, not single-gene disorders, epigenetic abnormalities, structural malformations, etc. An embryo with normal chromosomes can still have other problems.
- Myth 2: PGT-A increases the pregnancy rate. To be precise, it increases the "effective transfer rate" and "live birth rate per transfer," not the "pregnancy rate per cycle." For older patients, it might even feel like "getting pregnant is slower" because the number of transfers is reduced after screening.
- Myth 3: Deliberately accumulating embryos to do PGT-A. Repeated freeze-thaw cycles and long-term freezing may have potential effects on the embryo. While accumulating embryos, the mother's age is also increasing, and ovarian function may further decline.
- Myth 4: Normal PGT-A result = 100% transfer success. Even when transferring a euploid embryo, there is still a failure rate of about 30%-40% (depending on age, endometrial receptivity, uterine environment, etc.).
- Myth 5: PGT-A technology is the same in all reproductive centers. Differences exist in biopsy techniques, testing platforms, embryo culture conditions, and quality management systems between centers, leading to variations in the reliability of test results and subsequent pregnancy outcomes.
Frequently asked questions and clinical answers
Special situations and individualized decision-making
In clinical practice, the applicability of PGT-A needs to be more carefully evaluated in the following situations:
- Diminished Ovarian Reserve (DOR): Few eggs are retrieved, and the blastocyst formation rate is low, making it difficult to obtain a sufficient number of embryos for testing. This group needs thorough communication about the risk of having "no embryos to transfer" after PGT-A.
- Previous PGT-A all abnormal: If all blastocysts from one cycle are aneuploid, it is necessary to assess for high-risk factors for chromosomal abnormalities (such as mosaicism, translocation carrier status), and possibly change the testing plan or consider egg/sperm donation.
- Concurrent uterine factors: PGT-A addresses embryo issues. If there are conditions like intrauterine adhesions, thin endometrium, or chronic endometritis, the uterine problem needs to be treated first; otherwise, even transferring a euploid embryo may fail.
- Polycystic Ovary Syndrome (PCOS): PCOS patients usually retrieve more eggs, but whether the aneuploidy rate is increased is debated. The benefit of PGT-A in this group needs individualized assessment.
Doctor's Advice: PGT-A is a valuable assistive technology, but it is just one tool in the reproductive medicine toolbox, not a universal solution. The decision to use PGT-A needs to return to the most fundamental questions—your age, ovarian reserve, embryo potential, medical history, and family goals. Putting this information together and having a systematic decision-making conversation with your doctor is far more meaningful than blindly choosing or outright rejecting it.
This article is intended solely as educational material on assisted reproductive knowledge and does not constitute medical advice. Please consult a qualified reproductive medicine center for specific diagnosis and treatment plans.
— Reproductive Medicine Knowledge Base · PGT-A Special Topic —
Comments (0)